Primary Sites of Uveal Melanoma Associated with Distinct Survival Outcomes and Clinicopathological Features: A SEER Population-Based Study of 4359 Cases.
cancer-specific survival
choroid melanoma
ciliary body/iris melanoma
overall survival
uveal melanoma
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
07
2021
accepted:
11
08
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
We sought to investigate clinicopathological characteristics correlated with the prognosis of uveal melanoma (UM) patients and find the driving factors of prognosis for ciliary/iris melanoma relative to choroid melanoma. We collected patients with uveal melanoma between 1983 and 2012 from the Surveillance, Epidemiology, and End Results (SEER) database. Primary outcomes were evaluated as cancer-specific survival (CSS) and overall survival (OS). The Kaplan-Meier analysis was applied for the univariate analysis of CSS and OS and corresponding survival curves. Cox proportional hazards regression was used for multivariate analysis to value hazard ratio (HR) of ciliary body/iris melanoma subgroup versus choroid melanoma subgroup. A total of 4359 eligible patients were collected in our study. Novel potential prognostic factors for CSS and OS of UM were identified. Age at diagnosis, sex, primary tumor site, histologic subtype, tumor size, the extent of disease, and treatment were the independent prognostic factors for UM patients ( Age, sex, primary tumor site, histologic subtype, tumor size, the extent of disease, and treatment options are independent prognostic indicators for UM patients. Besides, the ciliary body/iris melanoma subgroup shows worse survival outcomes than choroid melanoma. Our findings offer inspiration to the individual treatment for UM patients with different primary sites.
Identifiants
pubmed: 34512005
doi: 10.2147/IJGM.S328910
pii: 328910
pmc: PMC8427688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5221-5232Informations de copyright
© 2021 Liang et al.
Déclaration de conflit d'intérêts
All authors declare that they have no conflicts of interest for this work.
Références
Ophthalmology. 2007 Oct;114(10):1925-31
pubmed: 17719643
Lancet. 1996 May 4;347(9010):1222-5
pubmed: 8622452
J AAPOS. 2012 Feb;16(1):10-6
pubmed: 22370659
Strahlenther Onkol. 2017 Nov;193(11):931-942
pubmed: 28879443
Retina. 2018 Oct;38(10):2010-2022
pubmed: 29528980
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Ophthalmology. 1990 Jun;97(6):769-77
pubmed: 2374681
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3282-7
pubmed: 12882771
Am J Ophthalmol. 1990 May 15;109(5):585-92
pubmed: 2333923
Eye (Lond). 2009 Dec;23(12):2152-60; quiz 2161-2
pubmed: 19876071
Retina. 2012 Jul;32(7):1363-72
pubmed: 22466491
Am J Ophthalmol. 1979 Jun;87(6):741-60
pubmed: 377973
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Hum Pathol. 1982 Feb;13(2):123-32
pubmed: 7076200
Invest Ophthalmol Vis Sci. 2013 Jan 23;54(1):652-6
pubmed: 23197684
Ophthalmology. 1995 May;102(5):844-51
pubmed: 7777286
Arch Ophthalmol. 1980 Nov;98(11):1975-9
pubmed: 7436829
Ophthalmology. 2003 May;110(5):962-5
pubmed: 12750098
Eur J Ophthalmol. 2010 Jan-Feb;20(1):194-200
pubmed: 19882527
Br J Ophthalmol. 1978 Jun;62(6):420-5
pubmed: 352389
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
J Clin Oncol. 2005 Nov 1;23(31):8076-80
pubmed: 16258106
Arch Ophthalmol. 2001 Jul;119(7):969-82
pubmed: 11448319
Graefes Arch Clin Exp Ophthalmol. 1999 Jul;237(7):558-67
pubmed: 10424306
Br J Ophthalmol. 2015 Nov;99(11):1550-3
pubmed: 25904122
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Arch Ophthalmol. 2000 Aug;118(8):1066-70
pubmed: 10922199